US2011280927A1PendingUtilityA1

Composition and dressing with nitric oxide

Assignee: ARAYA ABRAHAMPriority: Nov 21, 2008Filed: Nov 20, 2009Published: Nov 17, 2011
Est. expiryNov 21, 2028(~2.3 yrs left)· nominal 20-yr term from priority
A61P 3/10A61P 9/08A61P 29/00A61P 25/00A61P 17/02A61P 15/00A61P 17/00A61P 15/10A61L 15/44A61L 15/18A61L 2300/114A61L 2300/602A61L 26/0004A61L 2300/802A61L 26/0066A61L 15/58A61L 26/0052
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A dressing composition for use as a skin dressing comprises an elastomeric-adhesive composition, and a zeolite comprising releasably adsorbed nitric oxide. The zeolite may comprise a transition metal cation such as Co, Fe, Mn, Ni, Cu, Zn, Ag or a mixture thereof as an extra-framework metal cation, preferably Zn. The elastomeric adhesive composition may be a hydrocolloid-adhesive composition comprising, hydrocolloid and elastomer. The dressing composition releases nitric oxide, which may have beneficial effects, when used on wounds or moist skin, with a substantially constant release rate over a long period of time. A dressing including a layer of the dressing composition has a backing layer and may have a release liner removably attached to the skin-contacting surface of the dressing layer.

Claims

exact text as granted — not AI-modified
1 . A dressing composition for use as a skin dressing comprising:
 i) an elastomeric-adhesive composition, and   ii) a zeolite comprising releasably adsorbed nitric oxide.   
     
     
         2 . The composition of  claim 1  comprising from 99.5 to 30% by weight of an elastomeric-adhesive composition, and from 0.5 to 70% by weight of zeolite. 
     
     
         3 . The composition of  claim 1  wherein the zeolite is selected from zeolite P, zeolite A, zeolite X, zeolite Y and mixtures thereof. 
     
     
         4 . The composition of  claim 3  wherein the zeolite is zeolite A. 
     
     
         5 . The composition of  claim 1  wherein the zeolite comprises a transition metal cation as an extra-framework metal cation providing positive charge. 
     
     
         6 . The composition of  claim 5  wherein 20 molar % or more of the extra framework cation of the zeolite is a transition metal cation. 
     
     
         7 . The composition of  claim 5  wherein the transition metal cation is Co, Fe, Mn, Ni, Cu, Zn, Ag or a mixture thereof. 
     
     
         8 . The composition of  claim 1  wherein the zeolite comprises at least 0.5 mmol/g of releasably adsorbed nitric oxide. 
     
     
         9 . The composition of  claim 1  wherein the zeolite is a dry zeolite. 
     
     
         10 . The composition of  claim 1  wherein the volume mean particle diameter of the zeolite is from 0.1 to 20 μm, preferably from 0.5 to 10 μm. 
     
     
         11 . (canceled) 
     
     
         12 . The composition of  claim 1  wherein the elastomeric adhesive composition is a hydrocolloid-adhesive composition comprising, by weight of the hydrocolloid-adhesive composition, from 15 to 70% by weight of a hydrocolloid and from 30 to 85% by weight of an elastomer. 
     
     
         13 . The composition of  claim 1  further comprising an additional pharmaceutically active agent. 
     
     
         14 . The composition  claim 13  wherein the additional pharmaceutically active agent is a wound-treatment agent. 
     
     
         15 . (canceled) 
     
     
         16 . A dressing for application to skin comprising a backing layer holding a dressing layer comprising a skin contacting surface and the dressing composition of  claim 1 . 
     
     
         17 . The dressing of  claim 16  further comprising a release liner removably attached to the skin-contacting surface of the dressing layer. 
     
     
         18 . The composition of  claim 5  wherein 50 molar % or more of the extra framework cation of the zeolite is a transition metal cation. 
     
     
         19 . The composition of  claim 5  wherein the transition metal cation is Zn, Cu, Ag or a mixture thereof. 
     
     
         20 . A method for the treatment of the human or animal body by application thereto of a composition according to  claim 1 . 
     
     
         21 . The method for treatment of  claim 20  for treatment selected from the group consisting of: treatment of wounds, treatment of erectile dysfunction, treatment of anorgasmia, enhancement of transdermal drug delivery, vasodilation as a precursor to surgical insertion, treatment of skin diseases, treatment of neuropathy and treatment of inflammation.

Join the waitlist — get patent alerts

Track US2011280927A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.